Mercy BioAnalytics develops blood-based tests for early cancer detection using their Mercy Halo™ platform.

Mercy BioAnalytics

Mercy BioAnalytics is on a mission to save lives and relieve suffering across the globe through the early detection of cancer. We have developed a novel liquid biopsy assay platform which interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling detection of cancer even in at the earliest stages.

Novalis LifeSciences

Sozo Ventures

LabCorp

Hatteras Venture Partners

Broadway Angels

Bruker

American Cancer Society

iSelect Fund

The Perkins Fund

Mercy BioAnalytics, Inc.

As Mercy’s summer internship program wraps up, we want to extend our heartfelt thanks to Arielle Feuer and Christopher O'Connell for all your hard work and commitment! 
 
Over the past few months, you’ve brought enthusiasm, fresh perspectives, and dedication to team Mercy. We’re proud of the contributions you’ve made, and the skills you’ve developed during your time here. We're honored to have had you as part of the team!
 
#MercyBio #SummerInterns #EarlyDetection #CancerScreening

Team Mercy took a break from revolutionizing cancer screening to enjoy some well-deserved summer fun and team bonding at Kimball Farms!

We’re so grateful for the talented and dedicated individuals who make our team so special. Here’s to many more moments of fun and collaboration on the road to helping patients everywhere!

#MercyBio #CancerScreening #SummerPicnic #Kimballfarms

August 1st is Lung Cancer Awareness Day.

Did you know that 1 in 16 people will be diagnosed with lung cancer in their lifetime and that 5-year survival is 10 times higher for people diagnosed with localized versus metastatic disease? Early detection is a critical tool to help combat the devastating impact of this disease. 

At Mercy, we are proud to be developing the Mercy Halo Lung Cancer assay; a high performance, blood-based test designed to detect lung cancer at its earliest stages, when it’s most treatable.
 
To learn more about our research on the early detection of lung cancer please visit www.mercybio.com 

To learn more about current methods for lung cancer screening, visit https://lnkd.in/dZM9D6SY 

#worldlungcancerday #lungcancer #lungcancerawareness #cancerresearch #mercybio #earlycancerdetection

We’re pleased to share that we’ve been recognized by the Association for Diagnostics & Laboratory Medicine with the 2024 Disruptive Technology Award! 

This award aims to evaluate and elevate companies developing new diagnostic tools and technologies that have the potential to improve patient care, such as the groundbreaking Mercy Halo™ Ovarian Cancer Screening test, designed to detect ovarian cancer early when it’s most treatable. 

Congratulations to the other finalists, Dionysus Digital Health and Vitestro, whose technology has the potential to help patients everywhere.

And thank you to Adam Bonislawski for the great article!

https://lnkd.in/gtQw6k4P

#DTAC #ADLM2024 #EarlyCancerDetection #CancerResearch

We're pleased to share that our abstract, "Analytical and clinical performance of a novel ovarian cancer screening test in asymptomatic women" has been recognized with a Distinguished Abstract Award at the upcoming ADLM annual meeting. The abstract was also selected for a podium presentation as part of the Distinguished Abstracts session on Tuesday, July 30th.

In more good news, Mercy has also been selected as a finalist of the Disruptive Technology Award Competition at ADLM! 

Come join us at ADLM to learn more about the great things happening at Mercy! 

https://lnkd.in/grgTtDSe    

#ADLM #mercybio #earlycancerdetection #cancerresearch

On Sunday, the Mercy team proudly participated in the Ovations for the Cure of Ovarian Cancer Walk and Run Against Ovarian Cancer! We walked with survivors, families, and friends affected by this devastating disease and we were inspired by their strength and resilience.

Despite uncooperative weather, the Ovations team put on an incredible event, providing awareness, education, and support for all those affected by Ovarian Cancer.

Thank you to our amazing team members who joined forces to support this important cause and help make a difference. Together we will create a brighter future by achieving our mission of saving lives through the early detection of cancer.

#OvarianCancer #OvarianCancerAwareness #CancerResearch #EarlyDetection #MercyBio

More exciting news this week at Mercy Bio! 

We are proud to announce that we have been granted Breakthrough Device Designation from the FDA for the use of our Mercy Halo™ Ovarian Cancer Screening Test in asymptomatic, postmenopausal women.

Ovarian cancer is one of the leading causes of cancer death among women, with nearly 80% diagnosed in late stages when survival is poor. By screening for ovarian cancer and identifying it early when it is most treatable, we have the potential to dramatically increase the survivability of this deadly disease. 

We are thrilled by this Breakthrough Device Designation both as recognition of the amazing work that is happening at Mercy and by the opportunity to engage even more closely with the FDA to advance this critical screening test through regulatory approval and make it available to help save lives through early cancer detection.

See the press release here: https://lnkd.in/gUkkSvqu  
   
Learn more about the data from our landmark clinical study here: https://lnkd.in/gfAr-FDz

Thanks to Molika Ashford and GenomeWeb for the opportunity to discuss the important work being done at Mercy BioAnalytics, Inc. as we advance our blood-based ovarian cancer screening test towards FDA approval on the path to broad commercial deployment.

We’re thrilled to be presenting the results from our latest clinical study demonstrating exceptional sensitivity and specificity for the detection of the deadliest form of ovarian cancer – high grade serous ovarian carcinoma – in blood samples from our intended use population of asymptomatic women at the upcoming ASCO meeting. We will be presenting our work on June 3rd from 9:00 – 12:00, poster # 424. We encourage you to stop by to learn more, or feel free to message me directly to arrange a time to connect in Chicago!

Read the GenomeWeb story here: https://lnkd.in/eJF2bjC3

Learn more about our recent clinical study and ASCO presentation here: https://lnkd.in/egRjWR59

Today is a major milestone for Mercy BioAnalytics and an important advance on the path to improved ovarian cancer survivorship. In the abstract published by ASCO today, we are reporting clinical data utilizing a novel blood test that exhibits significant performance improvement over legacy technologies for ovarian cancer screening.

In a retrospective study including 1,300+ asymptomatic, post-menopausal women, the Mercy Halo Ovarian Cancer Screening Test detected 82% of high grade serous ovarian cancers with 98% specificity. This is a significant boost over traditional methods such as CA125 and transvaginal ultrasound and represents a critical advance in the pursuit of effective approaches for ovarian cancer screening.

We are excited to share our progress in the mission to save lives through the early detection of cancer and are looking forward to advancing the Mercy Halo Ovarian Cancer Test through upcoming validation studies and regulatory review.

Read more about our data here: https://lnkd.in/gziJHvhg

MERC

COM:MERCYBIO

Mercy BioAnalytics